A Single-dose, Open-label, Parallel-group Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Subjects With Varying Degrees of Renal Function
Phase of Trial: Phase I
Latest Information Update: 29 Apr 2019
Price : $35 *
At a glance
- Drugs Efinopegdutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 24 Apr 2019 Status changed from recruiting to completed.
- 29 Jun 2018 Status changed from not yet recruiting to recruiting.
- 11 Jun 2018 New trial record